Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and shelve its lead anti-cancer drug conjugate.
- Home |
- Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30%
Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30%
- March 17, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
